{"id":4754,"date":"2026-04-30T02:47:47","date_gmt":"2026-04-30T02:47:47","guid":{"rendered":"https:\/\/bangkokpeptides.com\/?page_id=4754"},"modified":"2026-08-17T09:09:44","modified_gmt":"2026-08-17T09:09:44","slug":"what-is-retatrutide","status":"publish","type":"page","link":"https:\/\/bangkokpeptides.com\/th\/what-is-retatrutide\/","title":{"rendered":"What is Retatrutide"},"content":{"rendered":"\n<!--\n============================================================================\nWHAT IS RETATRUTIDE \u2014 INFORMATIONAL ARTICLE\nURL: \/what-is-retatrutide\/\nPaste into a Gutenberg Custom HTML block on a new page.\n============================================================================\n-->\n\n<style>\n.bp-reta-art {\n font-family: 'Inter', 'Helvetica Neue', Arial, sans-serif;\n color: #1a1a1a;\n line-height: 1.7;\n max-width: 1100px;\n margin: 0 auto;\n padding: 0 1rem;\n box-sizing: border-box;\n}\n.bp-reta-art h1, .bp-reta-art h2, .bp-reta-art h3, .bp-reta-art h4 {\n letter-spacing: -0.02em;\n line-height: 1.15;\n color: #000;\n}\n.bp-reta-art .eyebrow {\n display: inline-block;\n font-size: 0.7rem;\n font-weight: 700;\n letter-spacing: 0.25em;\n text-transform: uppercase;\n color: #c7a33a;\n border-top: 1px solid #c7a33a;\n border-bottom: 1px solid #c7a33a;\n padding: 0.5rem 1.25rem;\n}\n.bp-reta-art .section-label {\n font-size: 0.75rem;\n font-weight: 700;\n letter-spacing: 0.2em;\n text-transform: uppercase;\n color: #000;\n padding-left: 1rem;\n border-left: 3px solid #c7a33a;\n margin: 4rem 0 1.5rem 0;\n}\n.bp-reta-art .lead {\n font-size: 1.2rem;\n line-height: 1.55;\n color: #333;\n margin: 0 0 2rem 0;\n}\n.bp-reta-art .body {\n font-size: 1rem;\n color: #333;\n margin: 0 0 1.25rem 0;\n}\n.bp-reta-art .gold-link {\n color: #c7a33a;\n text-decoration: none;\n border-bottom: 1px solid #c7a33a;\n}\n.bp-reta-art .gold-link:hover {\n background: #faf7ee;\n}\n.bp-reta-art .cta-btn {\n display: inline-block;\n background: #c7a33a;\n color: #000;\n font-size: 0.85rem;\n font-weight: 700;\n letter-spacing: 0.15em;\n text-transform: uppercase;\n padding: 1rem 2rem;\n text-decoration: none;\n border-radius: 3px;\n transition: background 0.2s;\n}\n.bp-reta-art .cta-btn:hover {\n background: #b39230;\n}\n.bp-reta-art .cta-btn-dark {\n background: #fff;\n color: #000;\n border: 1px solid #c7a33a;\n}\n\n\/* HERO *\/\n.bp-reta-hero {\n background: #0d0d0d;\n border: 1px solid #c7a33a;\n border-radius: 6px;\n overflow: hidden;\n display: grid;\n grid-template-columns: 1.1fr 1fr;\n align-items: stretch;\n margin: 3rem 0 4rem 0;\n}\n.bp-reta-hero-text {\n padding: 4rem 3rem;\n display: flex;\n flex-direction: column;\n justify-content: center;\n}\n.bp-reta-hero h1 {\n font-size: 3rem;\n font-weight: 800;\n color: #fff;\n margin: 0 0 1rem 0;\n line-height: 1.05;\n}\n.bp-reta-hero .tagline {\n font-size: 0.85rem;\n letter-spacing: 0.2em;\n text-transform: uppercase;\n color: #c7a33a;\n font-weight: 700;\n margin: 0 0 2rem 0;\n}\n.bp-reta-hero p {\n font-size: 1.05rem;\n color: #d4d4d4;\n line-height: 1.7;\n margin: 0 0 1.25rem 0;\n}\n.bp-reta-hero .hero-cta-row {\n display: flex;\n gap: 1rem;\n margin-top: 1rem;\n flex-wrap: wrap;\n}\n.bp-reta-hero-image {\n background: #fff;\n border-left: 1px solid #c7a33a;\n display: flex;\n align-items: center;\n justify-content: center;\n padding: 2rem;\n}\n.bp-reta-hero-image img {\n max-width: 100%;\n height: auto;\n max-height: 420px;\n object-fit: contain;\n}\n\n\/* TLDR \/ KEY POINTS *\/\n.bp-reta-tldr {\n background: #faf7ee;\n border: 1px solid #ecdfb8;\n border-left: 4px solid #c7a33a;\n padding: 2rem 2.25rem;\n margin: 0 0 3rem 0;\n border-radius: 4px;\n}\n.bp-reta-tldr h4 {\n font-size: 0.75rem;\n letter-spacing: 0.2em;\n text-transform: uppercase;\n margin: 0 0 1rem 0;\n color: #000;\n}\n.bp-reta-tldr ul {\n margin: 0;\n padding-left: 1.25rem;\n}\n.bp-reta-tldr li {\n font-size: 1rem;\n line-height: 1.6;\n color: #333;\n margin-bottom: 0.5rem;\n}\n.bp-reta-tldr li:last-child { margin-bottom: 0; }\n.bp-reta-tldr li strong { color: #000; }\n\n\/* TRIPLE-G EXPLAINER *\/\n.bp-reta-triple {\n display: grid;\n grid-template-columns: repeat(3, 1fr);\n gap: 1rem;\n margin: 1.5rem 0 2rem 0;\n}\n.bp-reta-triple > div {\n background: #fff;\n border: 1px solid #eaeaea;\n border-top: 4px solid #c7a33a;\n padding: 1.75rem 1.5rem;\n}\n.bp-reta-triple .pathway-name {\n font-size: 0.7rem;\n letter-spacing: 0.2em;\n text-transform: uppercase;\n color: #c7a33a;\n font-weight: 700;\n margin-bottom: 0.5rem;\n}\n.bp-reta-triple h4 {\n font-size: 1.15rem;\n margin: 0 0 0.75rem 0;\n color: #000;\n}\n.bp-reta-triple p {\n font-size: 0.92rem;\n line-height: 1.6;\n color: #444;\n margin: 0;\n}\n\n\/* TRIAL DATA TABLE *\/\n.bp-reta-trial {\n margin: 2rem 0;\n border: 1px solid #eaeaea;\n border-radius: 6px;\n overflow: hidden;\n}\n.bp-reta-trial-row {\n display: grid;\n grid-template-columns: 1fr 1.5fr 1.5fr;\n border-bottom: 1px solid #eaeaea;\n}\n.bp-reta-trial-row:last-child { border-bottom: none; }\n.bp-reta-trial-row > div {\n padding: 1rem 1.25rem;\n border-right: 1px solid #eaeaea;\n font-size: 0.95rem;\n}\n.bp-reta-trial-row > div:last-child { border-right: none; }\n.bp-reta-trial-header {\n background: #0d0d0d;\n}\n.bp-reta-trial-header > div {\n color: #fff;\n font-weight: 700;\n font-size: 0.75rem;\n letter-spacing: 0.15em;\n text-transform: uppercase;\n}\n.bp-reta-trial-row > div:first-child {\n background: #fafafa;\n font-weight: 700;\n color: #000;\n font-size: 0.85rem;\n}\n.bp-reta-trial-row.highlight > div:nth-child(2),\n.bp-reta-trial-row.highlight > div:nth-child(3) {\n background: #faf7ee;\n font-weight: 600;\n color: #000;\n}\n\n\/* PULL QUOTE *\/\n.bp-reta-pull {\n background: #0d0d0d;\n color: #fff;\n border-left: 4px solid #c7a33a;\n padding: 2.5rem 2.5rem;\n margin: 3rem 0;\n border-radius: 4px;\n}\n.bp-reta-pull p {\n font-size: 1.4rem;\n line-height: 1.45;\n font-weight: 600;\n color: #fff;\n margin: 0 0 1rem 0;\n letter-spacing: -0.01em;\n}\n.bp-reta-pull cite {\n font-size: 0.8rem;\n letter-spacing: 0.15em;\n text-transform: uppercase;\n color: #c7a33a;\n font-style: normal;\n font-weight: 700;\n}\n\n\/* COMPARISON TABLE *\/\n.bp-reta-compare {\n margin: 2rem 0;\n border: 1px solid #eaeaea;\n border-radius: 6px;\n overflow: hidden;\n}\n.bp-reta-compare-row {\n display: grid;\n grid-template-columns: 1fr 1.5fr 1.5fr 1.5fr;\n border-bottom: 1px solid #eaeaea;\n}\n.bp-reta-compare-row:last-child { border-bottom: none; }\n.bp-reta-compare-row > div {\n padding: 1rem 1.25rem;\n border-right: 1px solid #eaeaea;\n font-size: 0.95rem;\n}\n.bp-reta-compare-row > div:last-child { border-right: none; }\n.bp-reta-compare-header {\n background: #0d0d0d;\n}\n.bp-reta-compare-header > div {\n color: #fff;\n font-weight: 700;\n font-size: 0.75rem;\n letter-spacing: 0.15em;\n text-transform: uppercase;\n}\n.bp-reta-compare-row.highlight > div:nth-child(4) {\n background: #faf7ee;\n font-weight: 600;\n color: #000;\n}\n.bp-reta-compare-row > div:first-child {\n background: #fafafa;\n font-weight: 700;\n color: #000;\n font-size: 0.85rem;\n}\n\n\/* FAQ *\/\n.bp-reta-faq details {\n border: 1px solid #eaeaea;\n border-radius: 6px;\n margin: 0 0 0.75rem 0;\n background: #fff;\n}\n.bp-reta-faq summary {\n padding: 1.25rem 1.5rem;\n cursor: pointer;\n font-weight: 600;\n font-size: 1rem;\n color: #000;\n list-style: none;\n display: flex;\n justify-content: space-between;\n align-items: center;\n}\n.bp-reta-faq summary::after {\n content: \"+\";\n color: #c7a33a;\n font-size: 1.4rem;\n font-weight: 400;\n}\n.bp-reta-faq details[open] summary::after { content: \"\u2212\"; }\n.bp-reta-faq details > div {\n padding: 0 1.5rem 1.5rem 1.5rem;\n}\n.bp-reta-faq details p {\n margin: 0;\n font-size: 0.98rem;\n color: #333;\n line-height: 1.7;\n}\n\n\/* CITATIONS *\/\n.bp-reta-citations {\n background: #fafafa;\n border: 1px solid #eaeaea;\n padding: 2rem 2.25rem;\n margin: 2rem 0 3rem 0;\n border-radius: 4px;\n font-size: 0.85rem;\n}\n.bp-reta-citations h4 {\n font-size: 0.7rem;\n letter-spacing: 0.2em;\n text-transform: uppercase;\n margin: 0 0 1rem 0;\n color: #000;\n}\n.bp-reta-citations ol {\n margin: 0;\n padding-left: 1.25rem;\n}\n.bp-reta-citations li {\n margin-bottom: 0.75rem;\n line-height: 1.55;\n color: #444;\n}\n.bp-reta-citations li:last-child { margin-bottom: 0; }\n.bp-reta-citations a {\n color: #c7a33a;\n text-decoration: none;\n border-bottom: 1px solid #c7a33a;\n}\n\n\/* FINAL CTA *\/\n.bp-reta-final-cta {\n background: #0d0d0d;\n border: 1px solid #c7a33a;\n border-radius: 6px;\n padding: 4rem 3rem;\n margin: 4rem 0 2rem 0;\n text-align: center;\n}\n.bp-reta-final-cta h2 {\n color: #fff;\n font-size: 2.25rem;\n margin: 0 0 1rem 0;\n}\n.bp-reta-final-cta p {\n color: #d4d4d4;\n font-size: 1.05rem;\n max-width: 600px;\n margin: 0 auto 2rem auto;\n}\n\n\/* DISCLAIMER *\/\n.bp-reta-disclaimer {\n background: #0d0d0d;\n color: #fff;\n padding: 2rem;\n margin: 3rem 0;\n border-radius: 4px;\n border: 1px solid #c7a33a;\n}\n.bp-reta-disclaimer .label {\n display: inline-block;\n font-size: 0.7rem;\n font-weight: 700;\n letter-spacing: 0.2em;\n text-transform: uppercase;\n background: #c7a33a;\n color: #000;\n padding: 0.4rem 0.8rem;\n margin-bottom: 1rem;\n}\n.bp-reta-disclaimer p {\n color: #fff;\n font-size: 0.9rem;\n line-height: 1.6;\n margin: 0;\n}\n\n\/* MOBILE *\/\n@media (max-width: 768px) {\n .bp-reta-hero {\n grid-template-columns: 1fr;\n }\n .bp-reta-hero-image {\n order: -1;\n border-left: none;\n border-bottom: 1px solid #c7a33a;\n padding: 2rem;\n }\n .bp-reta-hero-text {\n padding: 2.5rem 1.75rem;\n }\n .bp-reta-hero h1 {\n font-size: 2rem;\n }\n .bp-reta-hero p {\n font-size: 0.98rem;\n }\n .bp-reta-triple {\n grid-template-columns: 1fr;\n }\n .bp-reta-trial-row {\n grid-template-columns: 1.2fr 1fr 1fr;\n }\n .bp-reta-compare-row {\n grid-template-columns: 1.2fr 1fr 1fr 1fr;\n }\n .bp-reta-trial-row > div,\n .bp-reta-compare-row > div {\n padding: 0.75rem 0.6rem;\n font-size: 0.78rem;\n }\n .bp-reta-trial-header > div,\n .bp-reta-compare-header > div {\n font-size: 0.62rem;\n letter-spacing: 0.08em;\n }\n .bp-reta-pull {\n padding: 2rem 1.5rem;\n }\n .bp-reta-pull p { font-size: 1.1rem; }\n .bp-reta-final-cta {\n padding: 2.5rem 1.5rem;\n }\n .bp-reta-final-cta h2 {\n font-size: 1.6rem;\n }\n .bp-reta-art .section-label {\n margin: 3rem 0 1.25rem 0;\n }\n}\n<\/style>\n\n<div class=\"bp-reta-art\">\n\n <!-- ============ HERO ============ -->\n <div style=\"text-align:center;margin-top:3rem;\">\n <span class=\"eyebrow\">A Plain-English Guide<\/span>\n <\/div>\n\n <div class=\"bp-reta-hero\">\n <div class=\"bp-reta-hero-text\">\n <p class=\"tagline\">What Is Retatrutide<\/p>\n <h1>Retatrutide: the triple-receptor peptide rewriting the weight-loss field.<\/h1>\n <p>Retatrutide is a synthetic peptide developed by Eli Lilly that produced the largest weight-loss results ever recorded in a Phase 2 obesity trial \u2014 an average of 24.2% body weight reduction at the highest dose over 48 weeks.<\/p>\n <p>Here&#8217;s what it actually is, how it works, what the trials show, and how it stacks up against semaglutide and tirzepatide.<\/p>\n <div class=\"hero-cta-row\">\n <a href=\"\/product\/retatrutide\/\" class=\"cta-btn\">View Retatrutide \u2192<\/a>\n <a href=\"#how-it-works\" class=\"cta-btn cta-btn-dark\">How It Works<\/a>\n <\/div>\n <\/div>\n <div class=\"bp-reta-hero-image\">\n <img decoding=\"async\" src=\"https:\/\/bangkokpeptides.com\/wp-content\/uploads\/2026\/04\/Retatrutide-10mg-m.jpg\"\n alt=\"Bangkok Peptides Retatrutide vial \u2014 research peptide Thailand\"\n loading=\"lazy\" \/>\n <\/div>\n <\/div>\n\n <!-- ============ TL;DR ============ -->\n <div class=\"bp-reta-tldr\">\n <h4>Quick Summary<\/h4>\n <ul>\n <li><strong>What it is:<\/strong> A synthetic peptide that activates three receptors at once \u2014 GLP-1, GIP, and glucagon. The first compound of its class to reach late-stage clinical trials.<\/li>\n <li><strong>Why it matters:<\/strong> In Eli Lilly&#8217;s Phase 2 trial, the highest dose produced 24.2% mean weight loss at 48 weeks \u2014 the largest reduction ever reported for an anti-obesity drug at this stage.<\/li>\n <li><strong>How it compares:<\/strong> Semaglutide (Ozempic, Wegovy) hits one receptor. Tirzepatide (Mounjaro, Zepbound) hits two. Retatrutide hits three.<\/li>\n <li><strong>Status:<\/strong> Currently in Phase 3 clinical trials. Not yet approved for medical use anywhere. Available as a research-grade peptide for laboratory use only.<\/li>\n <\/ul>\n <\/div>\n\n <!-- ============ WHAT IS IT ============ -->\n <h3 class=\"section-label\">What Retatrutide Actually Is<\/h3>\n <p class=\"lead\">Retatrutide is a synthetic peptide \u2014 a short chain of amino acids \u2014 designed to bind to three different receptors in the body simultaneously. Its developer, Eli Lilly, calls it a &#8220;triple-G agonist,&#8221; referring to the three pathways it activates: GLP-1, GIP, and glucagon.<\/p>\n\n <p class=\"body\">If you&#8217;ve heard of Ozempic, Wegovy, Mounjaro, or Zepbound, you&#8217;ve already encountered the family retatrutide belongs to. Those drugs work by activating one or two of the same receptors. Retatrutide is the next generation \u2014 it activates all three at once.<\/p>\n\n <p class=\"body\">It is currently in Phase 3 clinical trials and is not yet approved as a medicine in any major jurisdiction. The compound supplied by research peptide vendors, including Bangkok Peptides, is the same molecule being studied in those trials \u2014 provided strictly for laboratory and preclinical research use only.<\/p>\n\n <!-- ============ HOW IT WORKS ============ -->\n <h3 class=\"section-label\" id=\"how-it-works\">How It Works \u2014 the Triple-G Pathway<\/h3>\n <p class=\"body\">The body has many receptors that influence appetite, blood sugar, and energy use. Retatrutide targets three of them. Each one does something distinct:<\/p>\n\n <div class=\"bp-reta-triple\">\n <div>\n <div class=\"pathway-name\">Pathway 1<\/div>\n <h4>GLP-1<\/h4>\n <p>Reduces appetite. Slows gastric emptying so food stays in the stomach longer. Improves insulin response. This is the pathway semaglutide targets.<\/p>\n <\/div>\n <div>\n <div class=\"pathway-name\">Pathway 2<\/div>\n <h4>GIP<\/h4>\n <p>Improves how the body handles fat and sugar. Works alongside GLP-1 to enhance the satiety effect. This is the second pathway tirzepatide adds.<\/p>\n <\/div>\n <div>\n <div class=\"pathway-name\">Pathway 3<\/div>\n <h4>Glucagon<\/h4>\n <p>Increases energy expenditure \u2014 the body burns more calories at rest. Also reduces fat accumulation in the liver. This is the receptor unique to retatrutide.<\/p>\n <\/div>\n <\/div>\n\n <p class=\"body\">The key insight is the third pathway. Glucagon does something the other two don&#8217;t \u2014 it raises baseline calorie burn. Where GLP-1 and GIP work mostly on the input side (eating less, feeling full sooner, processing food differently), glucagon works on the output side (burning more energy and clearing fat from the liver).<\/p>\n\n <p class=\"body\">Activating all three at once is the reason retatrutide produces results that single- and dual-agonist drugs can&#8217;t match. You&#8217;re suppressing appetite, improving how the body handles food, and increasing energy expenditure \u2014 all from one molecule.<\/p>\n\n <!-- ============ THE TRIAL DATA ============ -->\n <h3 class=\"section-label\" id=\"trial-data\">What the Phase 2 Trial Showed<\/h3>\n <p class=\"body\">In June 2023, the New England Journal of Medicine published the results of the Phase 2 retatrutide trial conducted by Eli Lilly. The trial enrolled 338 adults with obesity (BMI \u226530) or overweight (BMI \u226527) with at least one weight-related condition. Participants received weekly subcutaneous injections of retatrutide at one of four doses, or placebo, for 48 weeks.<\/p>\n\n <p class=\"body\">The results, by dose:<\/p>\n\n <div class=\"bp-reta-trial\">\n <div class=\"bp-reta-trial-row bp-reta-trial-header\">\n <div>Weekly Dose<\/div>\n <div>Mean Weight Loss at 48 Weeks<\/div>\n <div>% Achieving \u226515% Loss<\/div>\n <\/div>\n <div class=\"bp-reta-trial-row\">\n <div>Placebo<\/div>\n <div>2.1%<\/div>\n <div>2%<\/div>\n <\/div>\n <div class=\"bp-reta-trial-row\">\n <div>1 mg<\/div>\n <div>8.7%<\/div>\n <div>27%<\/div>\n <\/div>\n <div class=\"bp-reta-trial-row\">\n <div>4 mg<\/div>\n <div>17.1%<\/div>\n <div>60%<\/div>\n <\/div>\n <div class=\"bp-reta-trial-row\">\n <div>8 mg<\/div>\n <div>22.8%<\/div>\n <div>75%<\/div>\n <\/div>\n <div class=\"bp-reta-trial-row highlight\">\n <div>12 mg<\/div>\n <div>24.2%<\/div>\n <div>83%<\/div>\n <\/div>\n <\/div>\n\n <p class=\"body\">For context: in the equivalent Phase 2 trials, semaglutide produced about 14.9% weight loss at the highest dose, and tirzepatide produced about 20.9%. Retatrutide&#8217;s 24.2% is the largest figure ever recorded in a Phase 2 obesity trial.<\/p>\n\n <p class=\"body\">The trial also showed that 83% of participants on the highest dose lost at least 15% of their body weight, and 26% lost at least 30%. To put 30% in perspective: that&#8217;s a 100kg person ending the trial at 70kg. From a single weekly injection. In just under a year.<\/p>\n\n <div class=\"bp-reta-pull\">\n <p>&#8220;The mean reduction in body weight at 48 weeks was 24.2% in the 12-mg group \u2014 the largest reduction observed to date in a Phase 2 trial of an anti-obesity medication.&#8221;<\/p>\n <cite>\u2014 Jastreboff et al., New England Journal of Medicine, 2023<\/cite>\n <\/div>\n\n <!-- ============ LIVER FAT ============ -->\n <h3 class=\"section-label\">The Liver-Fat Result<\/h3>\n <p class=\"body\">Beyond weight loss, retatrutide produced a result that surprised researchers: dramatic reductions in liver fat. A separate Phase 2 sub-study published in 2024 in Nature Medicine looked specifically at participants with non-alcoholic fatty liver disease (NAFLD) \u2014 a condition where fat accumulates in the liver and can progress to serious disease.<\/p>\n\n <p class=\"body\">After 48 weeks, participants on retatrutide showed an 81.4% mean reduction in liver fat content at the highest dose. 86% of participants on retatrutide had complete normalisation of liver fat content (defined as \u22645%), compared with 0% in the placebo group.<\/p>\n\n <p class=\"body\">This is the glucagon receptor at work. The liver is the body&#8217;s main site of glucagon activity, and engaging that receptor appears to drive fat clearance from liver tissue in a way that GLP-1-only and GLP-1+GIP drugs simply don&#8217;t replicate.<\/p>\n\n <!-- ============ DOSING ============ -->\n <h3 class=\"section-label\">How It&#8217;s Dosed in Trials<\/h3>\n <p class=\"body\">Retatrutide is administered as a once-weekly subcutaneous injection. Like other peptides in this class, the dose is titrated upward gradually \u2014 starting low and stepping up every four weeks \u2014 to allow the body to adapt and minimise gastrointestinal side effects.<\/p>\n\n <p class=\"body\">In the Phase 2 trial, the titration schedule for the 12 mg group looked roughly like this:<\/p>\n\n <p class=\"body\">Weeks 1\u20134 at 2 mg, weeks 5\u20138 at 4 mg, weeks 9\u201312 at 6 mg, weeks 13\u201316 at 8 mg, then 12 mg from week 17 onward. The &#8220;start low, go slow&#8221; approach is standard across the GLP-1 drug family because rapid titration produces severe nausea.<\/p>\n\n <p class=\"body\">Side effects in the trial were mostly gastrointestinal \u2014 nausea, diarrhoea, vomiting, constipation \u2014 and most were rated mild to moderate. They were also dose-dependent, which is why titration matters. Modest increases in heart rate were also observed, consistent with glucagon receptor activity.<\/p>\n\n <!-- ============ COMPARISON ============ -->\n <h3 class=\"section-label\">Retatrutide vs Semaglutide vs Tirzepatide<\/h3>\n <p class=\"body\">All three compounds belong to the same broad family of incretin-mimetic peptides, but they target different combinations of receptors. The differences in trial outcomes track directly with how many pathways each one engages.<\/p>\n\n <div class=\"bp-reta-compare\">\n <div class=\"bp-reta-compare-row bp-reta-compare-header\">\n <div>Property<\/div>\n <div>Semaglutide<\/div>\n <div>Tirzepatide<\/div>\n <div>Retatrutide<\/div>\n <\/div>\n <div class=\"bp-reta-compare-row highlight\">\n <div>Receptors<\/div>\n <div>GLP-1<\/div>\n <div>GLP-1 + GIP<\/div>\n <div>GLP-1 + GIP + Glucagon<\/div>\n <\/div>\n <div class=\"bp-reta-compare-row highlight\">\n <div>Class<\/div>\n <div>Single-agonist<\/div>\n <div>Dual-agonist<\/div>\n <div>Triple-agonist<\/div>\n <\/div>\n <div class=\"bp-reta-compare-row highlight\">\n <div>Generation<\/div>\n <div>First<\/div>\n <div>Second<\/div>\n <div>Third<\/div>\n <\/div>\n <div class=\"bp-reta-compare-row highlight\">\n <div>Brand Names<\/div>\n <div>Ozempic \/ Wegovy<\/div>\n <div>Mounjaro \/ Zepbound<\/div>\n <div>Not yet approved<\/div>\n <\/div>\n <div class=\"bp-reta-compare-row highlight\">\n <div>Phase 2 Weight Loss (peak)<\/div>\n <div>~14.9%<\/div>\n <div>~20.9%<\/div>\n <div>24.2%<\/div>\n <\/div>\n <div class=\"bp-reta-compare-row highlight\">\n <div>Approval Status<\/div>\n <div>FDA approved<\/div>\n <div>FDA approved<\/div>\n <div>Phase 3 trials<\/div>\n <\/div>\n <\/div>\n\n <p class=\"body\">A common question: is the difference between 20.9% (tirzepatide) and 24.2% (retatrutide) really that significant? The answer is yes \u2014 but the more interesting comparison is at the higher end of the response distribution. 26% of retatrutide participants lost \u226530% of their body weight. That category essentially didn&#8217;t exist in earlier trials. We&#8217;re talking results that approach what bariatric surgery produces.<\/p>\n\n <p class=\"body\">For a deeper side-by-side look, see our dedicated comparison: <a href=\"\/retatrutide-vs-tirzepatide-vs-semaglutide\/\" class=\"gold-link\">Retatrutide vs Tirzepatide vs Semaglutide<\/a>.<\/p>\n\n <!-- ============ WHAT'S NEXT ============ -->\n <h3 class=\"section-label\">Where Retatrutide Goes From Here<\/h3>\n <p class=\"body\">Eli Lilly began Phase 3 trials for retatrutide \u2014 the TRIUMPH program \u2014 in 2023, and these trials are ongoing. Phase 3 is the larger, longer-running stage that determines whether the drug gets regulatory approval for human use. Initial Phase 3 results are expected from 2026 onward, with potential FDA approval somewhere in the 2026\u20132027 window if the data holds.<\/p>\n\n <p class=\"body\">Until then, retatrutide remains an investigational compound. It is not approved as a medicine, supplement, or therapeutic in any major jurisdiction. The version supplied by research peptide vendors is intended exclusively for laboratory and preclinical research use, not human consumption.<\/p>\n\n <!-- ============ WHERE TO GET IT ============ -->\n <h3 class=\"section-label\">Sourcing Retatrutide for Research<\/h3>\n <p class=\"body\">Bangkok Peptides supplies retatrutide as a research-grade lyophilised peptide, third-party tested by Janoshik at the manufacturing stage and again across production batches and verified to \u226599% purity by HPLC\/MS. We stock 10mg, 20mg, and 30mg vials with same-day or next-day dispatch from Bangkok and tracked nationwide delivery across Thailand.<\/p>\n\n <p class=\"body\">For researchers based in Thailand specifically, we maintain a dedicated <a href=\"\/retatrutide-thailand\/\" class=\"gold-link\">Retatrutide Thailand<\/a> page covering domestic supply, delivery timeframes, and Thailand-specific storage considerations. The full <a href=\"\/product\/retatrutide\/\" class=\"gold-link\">retatrutide product page<\/a> includes current vial pricing, batch documentation, and Janoshik test reports.<\/p>\n\n <!-- ============ FAQ ============ -->\n <h3 class=\"section-label\">Frequently Asked Questions<\/h3>\n <div class=\"bp-reta-faq\">\n\n <details>\n <summary>Is retatrutide the same as Ozempic?<\/summary>\n <div>\n <p>No. Ozempic (and Wegovy) is the brand name for semaglutide, which targets only the GLP-1 receptor. Retatrutide targets three receptors \u2014 GLP-1, GIP, and glucagon \u2014 and is a different molecule entirely. Retatrutide also produces substantially larger weight loss in trials than semaglutide.<\/p>\n <\/div>\n <\/details>\n\n <details>\n <summary>Is retatrutide approved by the FDA?<\/summary>\n <div>\n <p>Not yet. Retatrutide is currently in Phase 3 clinical trials. Phase 3 results are expected from 2026 onward, with potential FDA approval in the 2026\u20132027 window if the trial data supports it. Until approval, retatrutide is supplied as a research-grade peptide for laboratory use only.<\/p>\n <\/div>\n <\/details>\n\n <details>\n <summary>How much weight did people lose in the trial?<\/summary>\n <div>\n <p>In Eli Lilly&#8217;s Phase 2 trial published in NEJM in 2023, participants on the highest dose (12 mg weekly) lost an average of 24.2% of their body weight over 48 weeks. 83% of participants in that group lost at least 15% of their body weight, and 26% lost at least 30%. These are the largest weight-loss results ever recorded in a Phase 2 obesity trial.<\/p>\n <\/div>\n <\/details>\n\n <details>\n <summary>Why is retatrutide more effective than semaglutide?<\/summary>\n <div>\n <p>Retatrutide activates three receptors simultaneously (GLP-1, GIP, glucagon) where semaglutide activates only one (GLP-1). The third receptor \u2014 glucagon \u2014 increases energy expenditure (calorie burning at rest) and reduces liver fat. GLP-1 and GIP mostly work on appetite and food processing. Adding glucagon to the mix turns on a different mechanism that the older drugs don&#8217;t engage.<\/p>\n <\/div>\n <\/details>\n\n <details>\n <summary>What are the side effects?<\/summary>\n <div>\n <p>In the Phase 2 trial, the most common side effects were gastrointestinal \u2014 nausea, diarrhoea, vomiting, constipation \u2014 most of them mild to moderate. Side effects were dose-dependent, which is why the dose is titrated upward gradually rather than starting at the full dose. Modest increases in heart rate were also observed, consistent with glucagon receptor activity. Long-term safety is still being established through Phase 3 trials.<\/p>\n <\/div>\n <\/details>\n\n <details>\n <summary>How is retatrutide administered?<\/summary>\n <div>\n <p>In clinical trials, retatrutide is administered as a once-weekly subcutaneous injection. The dose is titrated upward in 4-week increments to reduce gastrointestinal side effects \u2014 typically starting at 2 mg and stepping up every 4 weeks. As supplied by Bangkok Peptides, retatrutide is a lyophilised powder that requires reconstitution with bacteriostatic water, for laboratory research use only.<\/p>\n <\/div>\n <\/details>\n\n <details>\n <summary>What&#8217;s the difference between Phase 2 and Phase 3 trials?<\/summary>\n <div>\n <p>Phase 2 trials test a drug on a few hundred participants over a year or so to establish efficacy and identify side effects. Phase 3 trials are much larger (thousands of participants), longer (often 2+ years), and are the stage required for regulatory approval. Retatrutide cleared Phase 2 with the strongest weight-loss results in the field&#8217;s history. Phase 3 is now ongoing.<\/p>\n <\/div>\n <\/details>\n\n <details>\n <summary>Can you buy retatrutide in Thailand?<\/summary>\n <div>\n <p>Retatrutide is supplied as a research-grade peptide by vendors like Bangkok Peptides for laboratory and preclinical research use only. It is not approved as a medicine in Thailand or any other jurisdiction. See our dedicated <a href=\"\/retatrutide-thailand\/\" class=\"gold-link\">Retatrutide Thailand<\/a> page for domestic supply details.<\/p>\n <\/div>\n <\/details>\n\n <\/div>\n\n <!-- ============ CITATIONS ============ -->\n <div class=\"bp-reta-citations\">\n <h4>Key References<\/h4>\n <ol>\n <li>Jastreboff AM, Kaplan LM, Fr\u00edas JP, et al. <strong>Triple\u2013Hormone-Receptor Agonist Retatrutide for Obesity \u2014 A Phase 2 Trial.<\/strong> New England Journal of Medicine. 2023;389:514-526. <a href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2301972\" target=\"_blank\" rel=\"nofollow noopener\">nejm.org<\/a><\/li>\n <li>Sanyal AJ, Kaplan LM, Fr\u00edas JP, et al. <strong>Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial.<\/strong> Nature Medicine. 2024;30:2037-2048.<\/li>\n <li>Rosenstock J, Frias J, Jastreboff AM, et al. <strong>Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial.<\/strong> The Lancet. 2023;402(10401):529-544.<\/li>\n <li>Eli Lilly and Company. <strong>TRIUMPH Phase 3 Clinical Trial Program for Retatrutide.<\/strong> Ongoing trials registered at ClinicalTrials.gov.<\/li>\n <\/ol>\n <\/div>\n\n <!-- ============ FINAL CTA ============ -->\n <div class=\"bp-reta-final-cta\">\n <h2>Source Retatrutide for Research<\/h2>\n <p>10mg, 20mg, and 30mg vials available for same-day dispatch from Bangkok. \u226599% HPLC\/MS verified purity, third-party tested by Janoshik at the manufacturing stage and again across production batches.<\/p>\n <a href=\"\/product\/retatrutide\/\" class=\"cta-btn\">View Retatrutide \u2192<\/a>\n <\/div>\n\n <!-- ============ DISCLAIMER ============ -->\n <div class=\"bp-reta-disclaimer\">\n <span class=\"label\">\u26a0 Important Notice<\/span>\n <p><strong>Educational content for research context only.<\/strong> This article summarises published clinical trial data and is provided for educational purposes only. It does not constitute medical advice. Retatrutide is supplied by Bangkok Peptides strictly for laboratory and preclinical research use, by qualified researchers in appropriate laboratory environments. Not for human or veterinary use. Retatrutide is not approved as a medicine, supplement, or therapeutic product in Thailand or any other major jurisdiction at the time of writing.<\/p>\n <\/div>\n\n<\/div>\n\n\n\n<script type=\"application\/ld+json\">\n{\n \"@context\": \"https:\/\/schema.org\",\n \"@type\": \"Article\",\n \"@id\": \"https:\/\/bangkokpeptides.com\/what-is-retatrutide\/#bp-article\",\n \"headline\": \"What Is Retatrutide? The Triple-Receptor Peptide Rewriting the Weight-Loss Field\",\n \"description\": \"Plain-English guide to retatrutide \u2014 what it is, how it works, the Phase 2 trial that produced 24.2% mean weight loss, and how it compares to semaglutide and tirzepatide. Citations include NEJM 2023 and Nature Medicine 2024.\",\n \"image\": \"https:\/\/bangkokpeptides.com\/wp-content\/uploads\/2026\/04\/Retatrutide-10mg-m.jpg\",\n \"author\": {\n \"@type\": \"Organization\",\n \"name\": \"Bangkok Peptides\",\n \"@id\": \"https:\/\/bangkokpeptides.com\/#organization\"\n },\n \"publisher\": {\n \"@type\": \"Organization\",\n \"name\": \"Bangkok Peptides\",\n \"@id\": \"https:\/\/bangkokpeptides.com\/#organization\",\n \"logo\": {\n \"@type\": \"ImageObject\",\n \"url\": \"https:\/\/bangkokpeptides.com\/wp-content\/uploads\/2025\/11\/cropped-bp-tiger-master-solid-master-png-donotdelete.png\"\n }\n },\n \"datePublished\": \"2026-04-30\",\n \"dateModified\": \"2026-04-30\",\n \"mainEntityOfPage\": {\n \"@type\": \"WebPage\",\n \"@id\": \"https:\/\/bangkokpeptides.com\/what-is-retatrutide\/\"\n },\n \"about\": {\n \"@type\": \"ChemicalSubstance\",\n \"name\": \"Retatrutide\",\n \"alternateName\": [\"LY3437943\", \"Triple-G agonist\", \"Triple-hormone-receptor agonist\"],\n \"description\": \"Synthetic peptide triple-receptor agonist developed by Eli Lilly. Activates GLP-1, GIP, and glucagon (GCGR) receptors simultaneously. Produced 24.2% mean body weight reduction at the highest dose in the 48-week Phase 2 trial published in NEJM 2023. Currently in Phase 3 clinical trials.\"\n },\n \"citation\": [\n {\n \"@type\": \"ScholarlyArticle\",\n \"name\": \"Triple\u2013Hormone-Receptor Agonist Retatrutide for Obesity \u2014 A Phase 2 Trial\",\n \"author\": \"Jastreboff AM, Kaplan LM, Fr\u00edas JP, et al.\",\n \"datePublished\": \"2023\",\n \"isPartOf\": {\n \"@type\": \"Periodical\",\n \"name\": \"New England Journal of Medicine\"\n },\n \"url\": \"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2301972\"\n },\n {\n \"@type\": \"ScholarlyArticle\",\n \"name\": \"Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial\",\n \"author\": \"Sanyal AJ, Kaplan LM, Fr\u00edas JP, et al.\",\n \"datePublished\": \"2024\",\n \"isPartOf\": {\n \"@type\": \"Periodical\",\n \"name\": \"Nature Medicine\"\n }\n },\n {\n \"@type\": \"ScholarlyArticle\",\n \"name\": \"Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial\",\n \"author\": \"Rosenstock J, Frias J, Jastreboff AM, et al.\",\n \"datePublished\": \"2023\",\n \"isPartOf\": {\n \"@type\": \"Periodical\",\n \"name\": \"The Lancet\"\n }\n }\n ],\n \"mentions\": [\n { \"@id\": \"https:\/\/bangkokpeptides.com\/product\/retatrutide\/#bp-product\" }\n ],\n \"keywords\": \"what is retatrutide, retatrutide explained, retatrutide mechanism, triple agonist peptide, GLP-1 GIP glucagon, retatrutide phase 2, retatrutide weight loss, retatrutide vs semaglutide, retatrutide vs tirzepatide\"\n}\n<\/script>\n\n<script type=\"application\/ld+json\">\n{\n \"@context\": \"https:\/\/schema.org\",\n \"@type\": \"FAQPage\",\n \"@id\": \"https:\/\/bangkokpeptides.com\/what-is-retatrutide\/#bp-faq\",\n \"mainEntity\": [\n {\n \"@type\": \"Question\",\n \"name\": \"Is retatrutide the same as Ozempic?\",\n \"acceptedAnswer\": {\n \"@type\": \"Answer\",\n \"text\": \"No. Ozempic (and Wegovy) is the brand name for semaglutide, which targets only the GLP-1 receptor. Retatrutide targets three receptors \u2014 GLP-1, GIP, and glucagon \u2014 and is a different molecule entirely. Retatrutide also produces substantially larger weight loss in trials than semaglutide.\"\n }\n },\n {\n \"@type\": \"Question\",\n \"name\": \"Is retatrutide approved by the FDA?\",\n \"acceptedAnswer\": {\n \"@type\": \"Answer\",\n \"text\": \"Not yet. Retatrutide is currently in Phase 3 clinical trials. Phase 3 results are expected from 2026 onward, with potential FDA approval in the 2026\u20132027 window if the trial data supports it. Until approval, retatrutide is supplied as a research-grade peptide for laboratory use only.\"\n }\n },\n {\n \"@type\": \"Question\",\n \"name\": \"How much weight did people lose in the trial?\",\n \"acceptedAnswer\": {\n \"@type\": \"Answer\",\n \"text\": \"In Eli Lilly's Phase 2 trial published in NEJM in 2023, participants on the highest dose (12 mg weekly) lost an average of 24.2% of their body weight over 48 weeks. 83% of participants in that group lost at least 15% of their body weight, and 26% lost at least 30%. These are the largest weight-loss results ever recorded in a Phase 2 obesity trial.\"\n }\n },\n {\n \"@type\": \"Question\",\n \"name\": \"Why is retatrutide more effective than semaglutide?\",\n \"acceptedAnswer\": {\n \"@type\": \"Answer\",\n \"text\": \"Retatrutide activates three receptors simultaneously (GLP-1, GIP, glucagon) where semaglutide activates only one (GLP-1). The third receptor \u2014 glucagon \u2014 increases energy expenditure (calorie burning at rest) and reduces liver fat. GLP-1 and GIP mostly work on appetite and food processing. Adding glucagon to the mix turns on a different mechanism that the older drugs don't engage.\"\n }\n },\n {\n \"@type\": \"Question\",\n \"name\": \"What are the side effects of retatrutide?\",\n \"acceptedAnswer\": {\n \"@type\": \"Answer\",\n \"text\": \"In the Phase 2 trial, the most common side effects were gastrointestinal \u2014 nausea, diarrhoea, vomiting, constipation \u2014 most of them mild to moderate. Side effects were dose-dependent, which is why the dose is titrated upward gradually rather than starting at the full dose. Modest increases in heart rate were also observed, consistent with glucagon receptor activity. Long-term safety is still being established through Phase 3 trials.\"\n }\n },\n {\n \"@type\": \"Question\",\n \"name\": \"How is retatrutide administered?\",\n \"acceptedAnswer\": {\n \"@type\": \"Answer\",\n \"text\": \"In clinical trials, retatrutide is administered as a once-weekly subcutaneous injection. The dose is titrated upward in 4-week increments to reduce gastrointestinal side effects \u2014 typically starting at 2 mg and stepping up every 4 weeks. As supplied by Bangkok Peptides, retatrutide is a lyophilised powder that requires reconstitution with bacteriostatic water, for laboratory research use only.\"\n }\n },\n {\n \"@type\": \"Question\",\n \"name\": \"What's the difference between Phase 2 and Phase 3 trials?\",\n \"acceptedAnswer\": {\n \"@type\": \"Answer\",\n \"text\": \"Phase 2 trials test a drug on a few hundred participants over a year or so to establish efficacy and identify side effects. Phase 3 trials are much larger (thousands of participants), longer (often 2+ years), and are the stage required for regulatory approval. Retatrutide cleared Phase 2 with the strongest weight-loss results in the field's history. Phase 3 is now ongoing.\"\n }\n },\n {\n \"@type\": \"Question\",\n \"name\": \"Can you buy retatrutide in Thailand?\",\n \"acceptedAnswer\": {\n \"@type\": \"Answer\",\n \"text\": \"Retatrutide is supplied as a research-grade peptide by vendors like Bangkok Peptides for laboratory and preclinical research use only. It is not approved as a medicine in Thailand or any other jurisdiction. See our dedicated Retatrutide Thailand page for domestic supply details.\"\n }\n }\n ]\n}\n<\/script>\n","protected":false},"excerpt":{"rendered":"<p>A Plain-English Guide What Is Retatrutide Retatrutide: the triple-receptor peptide rewriting the weight-loss field. Retatrutide is a synthetic peptide developed by Eli Lilly that produced the largest weight-loss results ever recorded in a Phase 2 obesity trial \u2014 an average of 24.2% body weight reduction at the highest dose over 48 weeks. Here&#8217;s what it [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-4754","page","type-page","status-publish","hentry"],"blocksy_meta":{"has_hero_section":"disabled","styles_descriptor":{"styles":{"desktop":"","tablet":"","mobile":""},"google_fonts":[],"version":6}},"_links":{"self":[{"href":"https:\/\/bangkokpeptides.com\/th\/wp-json\/wp\/v2\/pages\/4754","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bangkokpeptides.com\/th\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/bangkokpeptides.com\/th\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/bangkokpeptides.com\/th\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/bangkokpeptides.com\/th\/wp-json\/wp\/v2\/comments?post=4754"}],"version-history":[{"count":5,"href":"https:\/\/bangkokpeptides.com\/th\/wp-json\/wp\/v2\/pages\/4754\/revisions"}],"predecessor-version":[{"id":8457,"href":"https:\/\/bangkokpeptides.com\/th\/wp-json\/wp\/v2\/pages\/4754\/revisions\/8457"}],"wp:attachment":[{"href":"https:\/\/bangkokpeptides.com\/th\/wp-json\/wp\/v2\/media?parent=4754"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}